Dilution of Share Value from Stock Options
First written in FY2018. 6 of 11 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
18 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「Twelfth Series Share Acquisition Rights: common shares 270,000; Thirteenth Series Share Acquisition Rights: common shares 270,000; Fourteenth Series Share Acquisition Rights: common shares 202,100; Fifteenth Series Share Acquisition Rights: common shares 384,000」
The Tenth through Fifteenth Series Share Acquisition Rights are outstanding, and the potential for dilution from potential shares continues to be disclosed. - FY2023RestatedAnnual report
「Twelfth Series Share Acquisition Rights: common shares 270,000; Thirteenth Series Share Acquisition Rights: common shares 270,000; Fourteenth Series Share Acquisition Rights: common shares 202,100; Fifteenth Series Share Acquisition Rights: common shares 384,000」
Confirms for the full fiscal year the existence of the performance-based Twelfth through Fifteenth Series Share Acquisition Rights and the related potential shares. - FY2023-Q2WorsenedAnnual report
「Twelfth Series Share Acquisition Rights Common shares 270,000 (Note 3) Thirteenth Series Share Acquisition Rights Common shares 270,000 (Note 3) Fourteenth Series Share Acquisition Rights Common shares 202,100 (Note 3) Fifteenth Series Share Acquisition Rights Common shares 384,000 (Note 3)」
The Twelfth through Fifteenth Series Share Acquisition Rights were newly disclosed, adding potential shares covering a total of 1,126,100 shares. The exercisable percentage is determined based on the achievement of targets such as net sales of ¥1 billion, ¥1.5 billion, ¥2 billion and ¥3 billion. - FY2022RestatedAnnual report
「(2) Diluted net income per share Increase in common shares (shares) 20,660 (of which, share acquisition rights (shares)) (20,660)」
Discloses diluted earnings including share acquisition rights in the calculation, continuing to indicate the potential for dilution of share value. - FY2022-Q3RestatedAnnual report
「(2) Diluted quarterly net income per share ¥32.60 Increase in common shares (shares) 26,315 (of which, share acquisition rights (shares)) (26,315)」
Discloses diluted quarterly net income per share including 26,315 shares subject to share acquisition rights, continuing to indicate the potential for dilution of share value. - FY2021RestatedAnnual report
「The share acquisition rights allocated to each holder may be exercised during the exercise period, up to the number specified for each of the cases listed below, only if net sales and operating income for any fiscal year from the fiscal year ending January 2021 through the fiscal year ending January 2025 meet the levels specified in (a) through (d).」
Continues to disclose exercise conditions for the Tenth and Eleventh Series Share Acquisition Rights linked to net sales and operating income levels for the fiscal years ending January 2021 through January 2025. - FY2021-Q1WorsenedAnnual report
「At a meeting of the Company's Board of Directors held on 20 May 2020, the Company resolved, pursuant to Articles 236, 238 and 240 of the Companies Act, to issue the Eleventh Series Share Acquisition Rights to the Company's directors and granted them as described below.」
In addition to the Tenth Series Share Acquisition Rights, share acquisition rights covering 142,200 shares were granted to 1 director as the Eleventh Series Share Acquisition Rights. The exercise conditions are based on net sales and operating income levels for the fiscal years ending January 2021 through January 2025. - FY2020Establishment of new share acquisition rightsAnnual report
「The share acquisition rights allocated to each holder may be exercised during the exercise period, up to the number specified for each of the cases listed below, only if net sales and operating income for any fiscal year from the fiscal year ending January 2021 through the fiscal year ending January 2025 meet the levels specified in (a) through (d).」
Following the expiration of the previous share acquisition rights, exercise conditions were established for the Tenth Series Share Acquisition Rights based on net sales and operating income levels for the fiscal years ending January 2021 through January 2025. - FY2020-Q2RestatedAnnual report
「① [Details of the stock option plan] No applicable matters.」
Reconfirms that no stock option plans, share acquisition rights or similar instruments remain outstanding. - FY2019MitigatedAnnual report
「The share acquisition rights expired on 31 January 2019 because the exercise conditions had not been met by that date.」
States that the Eighth and Ninth Series Share Acquisition Rights expired because the exercise conditions were not met, reducing the potential for dilution from potential shares. - FY2018First statedAnnual report
「As of the end of January 2018, potential shares from stock options totaled 2,393,000 shares, equivalent to 11.2% of the total 21,321,000 shares issued.」
Quantifies the potential dilution of per-share value if the share acquisition rights are exercised, based on 2,393,000 potential shares, equivalent to 11.2% of the total shares issued.